TrialTrials2022

Statistical analysis plan for the Dual mTorc Inhibition in advanCed/recurrent Epithelial ovarian, fallopian tube or primary peritoneal cancer (of clear cell, endometrioid and high-grade serous type, and carcinosarcoma) trial (DICE).

Consuelo Nóhpal de la Rosa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.